Neurimmune announces publication in Science Translational Medicine
The Swiss Federal Institute of Technology Zurich (ETH) and the University of Zurich are flagging up an impressive number of spin-off establishments in the Life Sciences. In order to perform high quality scientific research, a convenient location with a state-of-the-art facility and the proximity to top-class academic research centers is an asset. The BIO-TECHNOPARK® Schlieren-Zurich provides that environment for biotech companies with a healthy spread of firms at varying stages of business development, which range from recent start-ups to global players like Roche Glycart. Currently the Center has 43 member organizations, 37 of these are life science business start-ups and research groups from the Center for Clinical Research of the University and the University Hospital Zurich.